This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
ENTRESTO® (sacubitril/valsartan) resources
ENTRESTO is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF).1
For further information, please refer to the Entresto Summary of Product Characteristics
Explore our resources, designed to provide you with useful information on ENTRESTO and other relevant topics for healthcare professionals treating eligible patients with HFrEF.
The Heart Failure Foundation Course 2025 offers an insightful three-part promotional webinar series, designed for healthcare professionals seeking to deepen their understanding of HFrEF.
Click on the video thumbnails below to watch.
Chronic HFrEF – burden, symptoms and diagnosis
Optimising treatment for people with chronic HFrEF
Managing renal function in people with HFrEF
HFrEF, heart failure with reduced ejection fraction.
Reference
ENTRESTO (sacubitril/valsartan) Summary of Product Characteristics.
UK | November 2025 | FA-11548980
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.